Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Clinical and Molecular Genetic Risk Factors for Severe Familial Hypercholesterolemia.

Journal of lipid and atherosclerosis·2026
Same author

The Emerging Lipid Risk: Lipoprotein(a).

Korean circulation journal·2025
Same author

2024 KSoLA Update on New Lipid-Lowering Agents: Inclisiran and Bempedoic Acid.

Journal of lipid and atherosclerosis·2025
Same author

Escalating Lipid Therapy After Achieving LDL-C <70 mg/dL With Moderate-Intensity Statins in High-Risk Patients.

Korean circulation journal·2024
Same author

2024 KSoLA Consensus on Secondary Dyslipidemia.

Journal of lipid and atherosclerosis·2024
Same author

Moderate-Intensity Rosuvastatin/Ezetimibe Combination versus Quadruple-Dose Rosuvastatin Monotherapy: A Meta-Analysis and Systemic Review.

Yonsei medical journal·2023
Same journal

Multidisciplinary Rescue for a Lethal Triad: Severe Hypertriglyceridemia, Necrotizing Pancreatitis, and Abdominal Compartment Syndrome in Pregnancy.

Journal of lipid and atherosclerosis·2026
Same journal

Association of Smoking Status and Urinary Cotinine Levels With Lipoprotein(a) in Korean Adults.

Journal of lipid and atherosclerosis·2026
Same journal

Molecular and Genetic Aspects of Lipid Metabolism Disorders and Potential Targets for Gene Therapy.

Journal of lipid and atherosclerosis·2026
Same journal

Sex Differences in the Diagnosis and Treatment of Japanese Patients With Familial Hypercholesterolemia: A Retrospective Cohort Study.

Journal of lipid and atherosclerosis·2026
Same journal

Combination of Fimasartan and Statins in Patients With Hypertension and Dyslipidemia.

Journal of lipid and atherosclerosis·2026
See all related articles

Related Experiment Video

Updated: May 31, 2026

A Patient-Derived Xenograft Model for Venous Malformation
06:51

A Patient-Derived Xenograft Model for Venous Malformation

Published on: June 15, 2020

Treatment Target Discovery From Vasculo-Protective Phenotypes.

Sang-Hak Lee1

  • 1Division of Cardiology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.

Journal of Lipid and Atherosclerosis
|May 29, 2026
PubMed
Summary
This summary is machine-generated.

Genetic studies reveal that Cdkal1 deficiency in the liver boosts cholesterol transport. This finding offers new therapeutic targets for cardiovascular diseases and drug development.

Keywords:
CholesterolCoronary artery diseaseDrug developmentGenetics

More Related Videos

Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension
09:23

Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension

Published on: February 11, 2017

Assessment of Vascular Regeneration in the CNS Using the Mouse Retina
07:32

Assessment of Vascular Regeneration in the CNS Using the Mouse Retina

Published on: June 23, 2014

Related Experiment Videos

Last Updated: May 31, 2026

A Patient-Derived Xenograft Model for Venous Malformation
06:51

A Patient-Derived Xenograft Model for Venous Malformation

Published on: June 15, 2020

Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension
09:23

Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension

Published on: February 11, 2017

Assessment of Vascular Regeneration in the CNS Using the Mouse Retina
07:32

Assessment of Vascular Regeneration in the CNS Using the Mouse Retina

Published on: June 23, 2014

Area of Science:

  • Biochemistry
  • Genetics
  • Pharmacology

Background:

  • Genetic studies and bioinformatics accelerate the discovery of drug targets, particularly genes and proteins.
  • Research into protective lipid profiles has identified novel therapeutic targets and driven drug development.
  • High-density lipoprotein (HDL)-dependent cholesterol transport is a key area of atherosclerosis research.

Purpose of the Study:

  • To explore the association between hepatic Cdkal1 deficiency and cholesterol transport.
  • To identify novel therapeutic targets and inform drug development for cardiovascular conditions.

Main Methods:

  • Genetic analysis of populations with specific phenotypes.
  • Bioinformatic analysis of genetic data.
  • Biochemical studies investigating gene and protein functions.

Main Results:

  • A recent study reported an association between hepatic Cdkal1 deficiency and increased centripetal cholesterol transport.
  • Cdkal1 plays a role in regulating cholesterol transport pathways.

Conclusions:

  • Hepatic Cdkal1 deficiency presents a potential therapeutic target for managing cholesterol transport.
  • Further genetic analyses of diverse populations with vasculo-protective phenotypes are expected to yield additional treatment targets and drug development opportunities.